We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pacific Biosciences Unveils Sequel IIe for HiFi Sequencing
Read MoreHide Full Article
Pacific Biosciences of California, Inc. (PACB - Free Report) recently introduced the Sequel IIe System, the next instrument evolution powered by its Single Molecule, Real-Time (SMRT) Sequencing technology.This development is expected to boost Pacific Biosciences’ flagship platform — the Sequel system.
For investors’ note, the Sequel system is a nucleic acid sequencing platform based on SMRT technology. The Sequel System has been a significant contributor to Pacific Bioscience’s top line.
More on the Sequel IIe System
Backed by increased computational capacity and on-instrument data processing, this new system can directly generate highly accurate long reads (HiFi reads) faster and in a more cost-efficient way. It offers scientists a detailed view of genomes and transcriptomes.
The new Sequel IIe System makes HiFi sequencing accessible to any project where high accuracy, long read lengths and affordability are crucial.
The Sequel IIe System is equipped with hardware and software upgrades that enable users to work directly with the most valuable and informative sequencing data currently available — PacBio HiFi reads.
HiFi reads facilitate the precise and simultaneous detection of single nucleotide and structural variants, allowing breakthroughs in human genetics and greatly broadening the scope of SMRT Sequencing.
Market Prospect
Per a report by Allied Market Research, the global DNA sequencing market was valued at $6.24 billion in 2017 and is projected to reach $25.47 billion in 2025, at a CAGR of 19.0%. Hence, this launch comes at an ideal time.
Recent Development
In August, the company and molecular diagnostics company, Asuragen, announced a clinical research partnership aimed at developing molecular assays based on PacBio’s SMRT Sequencing technology. The initial goal of the collaboration will be to conduct research in support of assay development for the carrier screening market.
Price Performance
In the past three months, the stock has surged 218.5% compared with 10.5% growth of the industry.
Zacks Rank and Key Picks
Pacific Biosciences currently has a Zacks Rank # 3 (Hold).
Some better-ranked stocks from the broader medical space include Boston Scientific (BSX - Free Report) , DaVita (DVA - Free Report) and Thermo Fisher Scientific (TMO - Free Report) .
DaVita’ long-term earnings growth rate is estimated at 11.9%. The company presently carries a Zacks Rank #1.
Thermo Fisher’s long-term earnings growth rate is estimated at 15.5%. It currently carries a Zacks Rank #1.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2021.
Image: Bigstock
Pacific Biosciences Unveils Sequel IIe for HiFi Sequencing
Pacific Biosciences of California, Inc. (PACB - Free Report) recently introduced the Sequel IIe System, the next instrument evolution powered by its Single Molecule, Real-Time (SMRT) Sequencing technology.This development is expected to boost Pacific Biosciences’ flagship platform — the Sequel system.
For investors’ note, the Sequel system is a nucleic acid sequencing platform based on SMRT technology. The Sequel System has been a significant contributor to Pacific Bioscience’s top line.
More on the Sequel IIe System
Backed by increased computational capacity and on-instrument data processing, this new system can directly generate highly accurate long reads (HiFi reads) faster and in a more cost-efficient way. It offers scientists a detailed view of genomes and transcriptomes.
The new Sequel IIe System makes HiFi sequencing accessible to any project where high accuracy, long read lengths and affordability are crucial.
The Sequel IIe System is equipped with hardware and software upgrades that enable users to work directly with the most valuable and informative sequencing data currently available — PacBio HiFi reads.
HiFi reads facilitate the precise and simultaneous detection of single nucleotide and structural variants, allowing breakthroughs in human genetics and greatly broadening the scope of SMRT Sequencing.
Market Prospect
Per a report by Allied Market Research, the global DNA sequencing market was valued at $6.24 billion in 2017 and is projected to reach $25.47 billion in 2025, at a CAGR of 19.0%. Hence, this launch comes at an ideal time.
Recent Development
In August, the company and molecular diagnostics company, Asuragen, announced a clinical research partnership aimed at developing molecular assays based on PacBio’s SMRT Sequencing technology. The initial goal of the collaboration will be to conduct research in support of assay development for the carrier screening market.
Price Performance
In the past three months, the stock has surged 218.5% compared with 10.5% growth of the industry.
Zacks Rank and Key Picks
Pacific Biosciences currently has a Zacks Rank # 3 (Hold).
Some better-ranked stocks from the broader medical space include Boston Scientific (BSX - Free Report) , DaVita (DVA - Free Report) and Thermo Fisher Scientific (TMO - Free Report) .
Boston Scientific’s long-term earnings growth rate is estimated at 10%. The company presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
DaVita’ long-term earnings growth rate is estimated at 11.9%. The company presently carries a Zacks Rank #1.
Thermo Fisher’s long-term earnings growth rate is estimated at 15.5%. It currently carries a Zacks Rank #1.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2021.
Click here for the 6 trades >>